Feature

Artificial intelligence (AI) is blazing a technological trail that is transforming the way people work, interact, and even function. Though still in its infancy, recent developments in AI technologies have contributed significantly to automating and speeding up societal processes that were tedious and time-consuming even a year ago. While there’s much to be said about improved efficiencies, there’s something far more inherently powerful about AI that isn’t getting the headlines deserved: it can save lives. And with its innovative approach

Alarum Technologies (NASDAQ: ALAR) (TASE: ALAR) growth pace is shifting from hyper to warp. And that’s no exaggeration. In fact, in ALAR’s case, they are putting an exclamation point on that assessment, posting preliminary YTD revenues of $19.3 million, a total that, when formally published, will eclipse the income generated in all of 2022. Rightfully, that growth has led to an impressive rally in ALAR stock, which is over 31% higher since the start of the year. The potentially better

The single thing investors should know about a company’s stock price is that, at their best, they are undeniably imperfect. If they weren’t, prices wouldn’t fluctuate by large percentages based on a single analyst or retail trader comment. But any investor who watches financial headlines knows that they do. And regardless if they are megacaps like Tesla (NASDAQ: TSLA) or Amazon (NASDAQ: AMZN) or microcaps like KULR Technology Group (NYSE-Amer: KULR), millions of dollars of market cap can be erased

While OKYO Pharma Ltd. (NASDAQ: OKYO) stock is attracting bullish attention, trading today over 89% higher from its August low, recent updates support that the gain could just be the precursor to an even more appreciable rally. That sentiment is supported. Ironically, at $2.35 a share on Wednesday, OKYO stock is 66% lower than its 52-week high of $7.00 despite being better positioned than ever to expedite getting its flagship drug candidate to market. But that disconnect may close sooner